The long-term course and outcome of DAIH is unknown. A retrospective multicenter study assessing associations and long-term consequences of DAIH developing in a transplanted allograft is presented. Children with DAIH were followed from diagnosis until death, re-LT, or transfer of care and for a minimum of 1 year. A total of 31 patients of 1833 (1.7%) LT were identified; 29 followed for a median of 7.1 years (range, GGT, gamma glutamyl transferase; GSTT1, glutathione S-transferase T1; HLA, human lymphocyte antigen; LKM, anti-liver-kidney-microsomal antibody; mTOR, mammalian target of rapamycin; OKT3, muromonab-CD3; PTLD, post-transplant lymphoproliferative disorder.
| INTRODUCTION
Advances in liver transplantation have resulted in improved survival and better outcomes for most patients with liver disease. However, with these advances and longevity of liver allografts come late graft dysfunction that is often difficult to diagnose and represents a significant medical management issue. One of the important causes of chronic liver allograft dysfunction is DAIH, defined as late graft dysfunction, associated with autoimmune features in liver transplant patients without previous autoimmune hepatitis, and seen in 2.1%-6.6% of pediatric liver transplant recipients. [1] [2] [3] [4] [5] [6] [7] [8] [9] Although the underlying eti- phenotype with functional impairment akin to similar observations in many classical autoimmune diseases. 10, 11 Some of the risk factors associated with development of DAIH include number of acute rejection episodes, steroid dependence, 1 human lymphocyte antigen DR3 (HLA DR3) genotype, 4 female gender and age ≥40 years of the donor, 12 and GSTT1 donor/recipient mismatch. 13, 14 The poorly understood pathogenesis and natural history of DAIH have contributed to a lack of consensus on the optimal management of DAIH. [15] [16] [17] The concern for long-term allograft health is important for all transplant recipients, particularly those who receive organ transplants as infants and young children as the expectation is for them to maintain the same graft into adulthood. While there are several single-center reports highlighting risk factors associated with the development of DAIH and short-to midterm patient outcome, to the best of our knowledge, there are no reports of the natural history and long-term consequences of DAIH developing in a transplanted allograft. Given the role DAIH plays as a cause of chronic liver allograft dysfunction in pediatric liver transplant recipients, we sought to characterize the long-term course and outcome of DAIH in terms of complications, graft loss, need for retransplantation, and management across five large pediatric liver transplant centers, in a multicenter, multinational, retrospective study of pediatric liver transplant recipients.
| METHODS

| Patients
Children with a diagnosis of DAIH, followed at Yale New Haven eGFR was calculated from cystatin C as previously described. 21 Lastly, available data on serum transaminases, serum bilirubin, autoantibody titers, serum immunoglobulin G (IgG) levels obtained at time of diagnosis and yearly till last clinic visit were reviewed. The above data were extracted individually by each center. The Institutional Review Board at the participating centers approved this study.
| Statistics
Descriptive statistics were employed for data presentation; median, mean, standard deviation, range, and 25%-75% quintile were used for continuous variables and proportions for categorical variables.
Continuous variables were compared using a two-tailed Student's t test. 
| RESULTS
Thirty
| Immunosuppressive therapy at diagnosis
Three patients were on an antimetabolite at the time of diagnosis (298-365) ng/mL (measured in two patients).
| Post-transplant complications pre-DAIH diagnosis
Fifteen patients (52%) had no episode of acute rejection preceding the diagnosis of DAIH; eight patients (27.5%) had one acute rejection episode, one patient (3.4%) had two, and four patients (13.7%) had four or more acute rejection episodes preceding diagnosis of DAIH.
We were unable to retrieve information on preceding acute rejection episodes in one patient. Only one patient had an episode of acute rejection preceding the diagnosis of DAIH by less than 6 months; the majority of acute rejection episodes occurred greater than 6 months prior to a diagnosis of DAIH being made; additionally, the majority of the acute rejection episodes occurred greater than 6 months post-liver transplant. Of the 11 patients with trough tacrolimus levels ≥6 ng/mL at the time of diagnosis, seven had ≥1 episodes of acute rejection preceding the diagnosis of DAIH.
There was a past history of CMV infection predating the diagnosis of DAIH in two patients with one of the patients developing CMV disease. Early tonsillar PTLD occurred in one patient prior to the diagnosis of DAIH and leiomyosarcoma in a second patient. Biliary complications (biliary strictures) predated the diagnosis of DAIH in six patients.
| DAIH-long-term course and therapy
Twenty-one patients (72%) were placed on steroids once diagnosis was made, with a mean starting dose of 0.66±0.68 mg/kg/d (range: 0.5-2 mg/kg/d). Antimetabolite therapy with azathioprine or mycophenolate mofetil was initiated in 14 patients and one patient, respectively, once the diagnosis of DAIH was made. The 16 patients on tacrolimus at diagnosis remained on tacrolimus, and the 13 on cyclosporine remained on cyclosporine. The details of the treatment regimens used following diagnosis of DAIH for each patient are shown in Table 2A .
The median (range) of serum ALT, GGT, and total bilirubin at years 1, 5, 10, 13 post-diagnosis and at last follow-up is shown in Table 2B . Seventeen patients (58%) had a history of disease exacerbation:
Eight patients (27.5%) had at least one documented episode of disease flare, and nine patients (31%) had two or more documented episodes of disease flare. Disease exacerbations were biopsy-proven in all but one patient in whom two episodes of liver enzyme abnormality were attributed to disease flares without biopsy support; thus, a repeat liver biopsy was required in 58% of patients following the initial biopsy performed at time of diagnosis.
At the time of last follow-up, 18 patients (62%) were receiving steroids (17 prednisone, one budesonide), eight mycophenolate (27.5%), 13 azathioprine (44.8%), and two sirolimus (6.8%). Sirolimus was complementary (with tacrolimus) in the two patients. There were more patients on tacrolimus (68.9%) compared to cyclosporine (24.1%), suggesting that some patients were converted to tacrolimus over the follow-up period. Despite this, abnormal liver enzymes >2X ULN was observed in 38% of patients at time of last follow-up, most commonly GGT; of these, two patients were on steroids and mycophenolate, seven patients were on tacrolimus, steroids, and an antimetabolite, one patient was on tacrolimus and azathioprine, and one patient was on tacrolimus and sirolimus. Elevated serum GGT was attributed to bile duct injury in three patients, ductopenia in two patients, and biliary stricture in one patient. For the remaining patients, the elevated GGT was thought to be reflective of the liver disease.
Serum aminotransferase and bilirubin levels at time of last follow-up between patients who were off steroids vs on steroids as well as between patients who were off antimetabolites vs on antimetabolites are shown in Table 3 . The small numbers preclude satisfactory statistical analysis. Serum GGT at time of last follow-up tended to be lower if patients were off antimetabolites vs being on antimetabolites (Table 3) . working group on liver allograft pathology for DAIH include lymphocytic cholangitis (inflammatory bile duct damage). 22 One patient died from a non-DAIH-related pathology.
| DAIH-Long-term complications
| DISCUSSION
This retrospective multicenter study describes observational associations, natural history, and long-term consequences of DAIH developing in a transplanted allograft in a cohort of pediatric liver transplant recipients followed for up to 15 years following a diagnosis of DAIH. To the best of our knowledge, this is the first such report detailing these aspects over a prolonged period (median [range] follow-up-7.1 years [1.6-15 years]) in a large multicenter cohort. In our multicenter cohort, DAIH was diagnosed in 1.7% of pediatric liver transplant recipients close to the lower range quoted in single-center reports of 2.1%-6.6%. [1] [2] [3] [4] [5] [6] [7] [8] [9] With regard to events preceding the diagnosis of DAIH, one could argue that the cyclosporine trough and two-hour peak levels at the time of diagnosis are fairly representative of the median duration from transplantation, that is, 5.3 years; however, the tacrolimus trough levels appear somewhat higher than would be expected at this time from transplant. To address this discrepancy, we investigated for immunological events preceding the diagnosis of DAIH, specifically the occurrence of acute rejection. Even though the number of acute rejection episodes has been previously reported to be a risk factor associated with development of DAIH, we found within our cohort that only 48% of patients developed acute rejection pre-DAIH diagnosis; and only one patient experienced acute rejection in the 6 months preceding the diagnosis of DAIH. Within the SPLIT (Studies of Pediatric Liver Transplantation) cohort, 66% of patients had one or more documented episodes of acute rejection within the first 10 years after primary liver transplant. 23 With regard to other possible triggers, CMV infection or PTLD was not common in our cohort before the diagnosis of DAIH.
Following the diagnosis of DAIH, there was a rapid fall in serum aminotransferase levels, which then fluctuated throughout the period of follow-up ( Figure 1 ). This observation draws attention to the currently accepted treatment paradigm and suggests we are either not optimizing our treatments, or perhaps the current treatment options may not be optimal and new treatment approaches should be studied. This is also supported by the fact that disease exacerbation was reported in a little over half of the patients, and despite ~two-thirds of patients remaining on steroids and ~three-fourths remaining on an antimetabolite at last follow-up, the median GGT levels remained higher than the ULN (Table 3 ). Another possibility is that centers may have been more willing to tolerate aminotransferases in the 40s to 50s rather than risk consequences of further increased immunosuppression.
We next questioned if remaining on steroids or antimetabolites for long term would influence liver enzyme levels; however, the serum aspartate and alanine aminotransferases did not differ at time of last follow-up between patients who remained on/off steroids or antimetabolites. Serum GGT tended to be lower in those off antimetabolites vs those who remained on antimetabolites at last follow-up, suggesting these may have been patients who had done well and were weaned off antimetabolites. These findings may be related to guarded efficacy of the current therapies for DAIH; however, considering the retrospective study design, it may simply reflect patient-specific tailoring of immunosuppressive medications where more stable patients are weaned off steroids or antimetabolites. We also acknowledge that as immunosuppressive modifications were done according to contemporaneous local practice, it is somewhat difficult to determine the efficacy of additional steroids or antimetabolites.
Liver biopsies were not done routinely in our patients, and the correlation between abnormal liver enzymes and histological changes is unclear. It is possible that routine surveillance liver biopsy in patients with DAIH will provide a better tool for follow-up and optimization of therapy.
Although most of the patients with DAIH remained stable with normal graft function, the consequence of this persistent biochemical abnormality with presumed continued inflammation in the allograft was the development of chronic graft histological changes of progressive fibrosis-cirrhosis with portal hypertension (n=4) necessitating liver retransplantation in two patients. Portal hypertension as a direct consequence of DAIH has not been previously reported in published series; however, none of the published series had followed the outcomes of patients up to 15 years after the diagnosis of DAIH. [1] [2] [3] 6, 7, 9, 13, 24, 25 It is unlikely that portal hypertension was secondary to a biliary or vascular problem as none of the patients with portal hypertension had biliary obstruction and even though one of the four patients with portal hypertension had portal vein thrombosis (3.4%), the remaining patients had no vascular complication. Within the SPLIT cohort, portal vein thrombosis was reported in 7% of patients. 26 Re-liver transplantation was seen in 6.9% of patients in our cohort, compared to 12% of 10-year survivors in the SPLIT cohort. 23 It is interesting that elevated serum GGT levels appeared to be the commonest liver enzyme abnormality noted at last follow-up and was attributed to biliary stricture in only one patient, and bile duct injury and ductopenia in another one-fourth and one-fifth of patients, respectively; importantly, chronic rejection was a cause of late graft loss in one patient. DAIH has always been recognized histologically to comprise a plasma cell-rich mononuclear portal inflammatory infiltrate with varying degrees of interface hepatitis, in the absence of vascular or bile duct involvement. 27 It is tempting to speculate if T A B L E 3 Variability in liver enzyme levels on/off treatment at last follow-up chronic damage to bile ducts and elevated GGT. It is worth mentioning that elevated serum GGT at the levels observed in Figure 1B is not a characteristic of autoimmune hepatitis in non-transplanted children. however, as is demonstrated in Figure 1 , liver enzymes remained >2X ULN in a little over one-third of the patients over the course of the disease, supporting the conclusion that their disease was not responsive to the treatment being given.
| CONCLUSION
DAIH is an uncommon chronic complication following pediatric liver transplantation that requires prolonged and augmented immunosuppressive treatment. Our report suggests long-term outcomes are not benign as DAIH is associated with continued allograft dysfunction that may lead overtime to bile duct injury, chronic graft histological changes of progressive fibrosis-cirrhosis and portal hypertension necessitating liver retransplantation in small number of patients. This is the first report documenting bile duct injury and portal hypertension as complications of DAIH. The role of routine surveillance liver biopsies in the treatment of DAIH and tailoring of IS based on these biopsies should be further explored in a prospective study setting.
Importantly, improved understanding of the very early determinants of bile duct injury along with surrogate markers of aberrant inflammatory processes should be sought in an attempt to uncover truly effective therapy. 
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